| 期刊論文| 1. | 姜紹青(20141200)。Ado-trastuzumab Emtansine：第一個用於固態腫瘤之抗體結合藥品。腫瘤護理雜誌，14(2)，19-26。 延伸查詢 | | 2. | 盧彥伸(20130700)。乳癌的標靶治療。臺灣醫學，17(4)，412-419。 延伸查詢 | | 3. | Bachelot, T.、Romieu, G.、Campone, M.、Diéras, V.、Cropet, C.、Dalenc, F.、Labbe-Devilliers, C.(2013)。Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study。The Lancet Oncology，14(1)，64-71。  | | 4. | Bender, B. C.、Schaedeli-Stark, F.、Koch, R.、Joshi, A.、Chu, Y. W.、Rugo, H.、Gupta, M.(2012)。A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer。Cancer Chemotherapy and Pharmacology，70(4)，591-601。 | | 5. | Borneman, T.(2013)。Assessment and management of cancerrelated fatigue。Journal of Hospice and Palliative Nursing，15(2)，77-86。 | | 6. | Bourdeanu, L.、Luu, T.(2013)。Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer。Clinical Journal of Oncology Nursing，17(5)，58-62。 | | 7. | Diéras, V.、Harbeck, N.、Budd, G. T.、Greenson, J. K.、Guardino, A. E.、Samant, M.、Krop, I. E.(2014)。Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis。Journal of Clinical Oncology，32(25)，2750-2757。 | | 8. | Geyer, C. E.、Forster, J.、Lindquist, D.、Chan, S.、Romieu, C. G.、Pienkowski, T.、Cameron, D.(2006)。Lapatinib plus capecitabine for HER2-positive advanced breast cancer。The New England Journal of Medicine，355(26)，2733-2743。 | | 9. | Kirshbau, M.(2010)。Cancer-related fatigue: A review of nurisng interventions。British Journal of Community Nursing，15(5)，214-219。 | | 10. | Krop, I. E.、Kim, S. B.、Ganzález-Martin, A.、LoRusso, P. M.、Ferrero, J. M.、Smitt, M.、Wildiers, H.(2014)。Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomized, open-label, phase 3 trial。The Lancet Oncology，15(7)，689-699。 | | 11. | Oostra, D. R.、Macrae, E. R.(2014)。Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer。Breast Cancer: Targets and Therapy，6，103-113。 | | 12. | Peddi, P. F.、Hurvitz, S. A.(2014)。Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptors 2 (HER2)-positive metastatic breast cancer: Latest evidence and clinical potential。Therapeutic Advances in Medical Oncology，6(5)，202-209。 | | 13. | Radovich, P.(2011)。The multiple causes and myriad presentations of thrombocytopenia。American Nurse Today，6(1)，9-12。 | | 14. | Smith, N. Z.(2012)。Treating metastatic breast cancer with systemic chemotherapies: Current trends and future perspectives。Clinical Journal of Oncology Nursing，16(2)，33-43。 | | 15. | Swain, S. M.、Kim, S. B.、Cortés, J.、Ro, J.、Semiglazov, V.、Campone, M.、Baselga, J.(2013)。Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomized, double-blind, placebo-controlled phase 3 study。The Lancet Oncology，14(6)，464-471。 | | 16. | Uppal, H.、Doudement, E.、Mahapatra, K.、Darbonne, W. C.、Bumbaca, D.、Shen, B. Q.、Ramakrishnan, V.(2015)。Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)。Clinical Cancer Research，21(1)，123-133。 | | 17. | Verma, S.、Miles, D.、Gianni, L.、Krop, I. E.、Welslau, M.、Baselga, J.、Blackwell, K.(2012)。Trastuzumab emtansine for HER2-positive advanced breast cancer。The New England Journal of Medicine，367(19)，1783-1791。 | | 18. | Winkeljohn, D.(2013)。Diagnosis, treatment, and management of immune thrombocytopenia。Clinical Journal of Oncology Nursing，17(6)，664-666。 | | 19. | Wolff, A. C.、Hammond, M. E. H.、Hicks, D. G.、Dowsett, M.、McShane, L. M.、Allison, K. H.、Hayes, D. F.(2013)。Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update。Journal of Clinical Oncology，31(31)，3997-4013。 | | 20. | Yan, H.、Endo, Y.、Shen, Y.、Rotstein, D.、Dokmanovic, M.、Mohan, N.、Wu, W. J.(2016)。Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity。Molecular Cancer Therapeutics，15(3)，480-490。 | 其他| 1. | 衛生福利部統計處(2014)。102年死因統計結果分析，http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312andfod_list_no=5150。 延伸查詢 | | 2. | 羅氏(2014)。賀癌寧，http://www.roche.com.tw/content/dam/roche_taiwan/zh_TW/download/Kadcyla.pdf。 | |